The Company fell -1.5% and finished at $123.47.
Advertisement
The recent traded volume of 5.15 million shares higher than its average volume of 1.44 million shares. We don’t anticipate major top-line beats from the products that can be tracked by IMS weekly metrics, but there is always the potential for companies such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, Incyte, Regeneron Pharmaceuticals or Vertex Pharmaceuticals to deliver as part of their strong ongoing product launches which aren’t captured as well by IMS. The stock has a market cap of $28.08 billion and a PE ratio of 189.64. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock is now offering a return on equity of 1.80% while the return on assets is at 1.10% and the return on investment is at 1.60%. It measures a firm’s efficiency at generating profits from every unit of shareholders’ equity (also known as net assets or assets minus liabilities).
The sales growth quarter on quarter is at 16.80% while the total number of outstanding shares are at 225.06. Following the completion of the sale, the executive vice president now directly owns 42,706 shares in the company, valued at $5,944,675.20. Shares were Upgraded by Credit Suisse on Jul 11, 2016 to ” Outperform” and Lowered the Price Target to $ 165 from a previous price target of $186.Alexion Pharmaceuticals was Upgraded by Citigroup to ” Buy” on Jun 27, 2016.
The performance (Year to Date) is now at -35.27%. The stock is now trading down its SMA 50 of $180.14. If the YTD value is Positive, this means the stock is appreciating. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $221 and the lowest price target forecast is $145. Finally, Leerink Swann restated a “buy” rating and set a $216.00 price target (down from $217.00) on shares of Alexion Pharmaceuticals in a research note on Saturday, March 19th. Now the stock has been rated as “Buy” from 4 Analysts. The current consensus target price from Zacks Research is presently at $28.428 for the company. During the same quarter in the prior year, the company posted $1.28 EPS. $257 is the highest target while $154 is the lowest.
Advertisement
The Cheshire, CT-based pharmaceutical company entered the rare disease sector in 2007 with Soliris in PNH (paroxysmal nocturnal hemoglobinuria), added aHUS (atypical hemolytic uremic syndrome) in 2014, and reported $2.6 billion in worldwide sales past year, according to the analyst note.
